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Abstract 
Renal anemia is a common complication of chronic renal failure caused by erythropoietin deficiency; 
targeting erythropoietin is a common approach to renal anemia treatment. This paper describes the role 
of erythropoietin and others drugs in renal anemia treatment, as well as the cause of erythropoietin 
resistance. 
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The loss in whole or in part of kidney function 
results in renal failure, representing a significant 
threat to human health. “Renal anemia” refers to 
the various factors that cause erythropoietin-
related or toxic uremic plasma substances to 
interfere with red blood cell metabolism, leading 
to anemia. Renal anemia is a common 
complication of chronic renal insufficiency, which 
is related to various degrees of renal dysfunction. 
Erythropoietin (EPO) is a 34000 Da glycoprotein 
the main chain of which is comprised of 193 
amino acids. EPO a hormone-like substance 
secreted 90 % by renal interstitial cells and 10 % 
by liver cells. The kidney is the organ most 
responsible for controlling the level of EPO in 
serum, and any damage to renal tubular or 
glomerular tissue can inhibit the production of 
EPO and cause renal tissue ischemia and 
hypoxia, which can then further induce the 
formation of EPO [1]. EPO cannot be directly 
stored in the body after it is produced, but rapidly 
enter the metabolic process [2]. In general, 
serum EPO levels are regulated by the feedback 
regulation of hemoglobin and red blood cell 
pressure – once the feedback regulation appears 
abnormal (i.e., fluctuating EPO levels), the body 
undergoes a sustained rise in serum EPO levels 
that ultimately lead to kidney damage [3]. 
 
ERYTHROPOIETIN AND RENAL ANEMIA 
 
EPO can stimulate the proliferation and 
differentiation of cells in the bone marrow [4], and 
is a humoral factor that enhances the formation 
of red blood cells. EPO can also promote the 
differentiation of stem cells into the red blood cell 
line, and promote the synthesis of hemoglobin 
and the flow of blood into peripheral blood 
vessels [5]. EPO, activated by EPO receptors, 
promotes the differentiation and proliferation of 
the burst-forming unit-erythroid (BFU-E) cells to 
transform the red line into a mature red blood 
cells [6] (Figure 1).  
 
In this review, we found that EPO treatment can 
significantly improve renal anemia patients in 
terms of oxygen level, immune function, and so 
on; that the use of EPO can reduce transfusion-
related complications such as iron overload or 
blood infection [7]. To this effect, erythropoietin 
not only creates mature red blood cells but also 
has   an   important   role   in   heart   protection.  
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Figure 1: The process of erythropoiesis. Depend on Epo and EpoR, erythroid progenitors differentiation into 
mature red blood cells. Quote from Ann Hematol2014; 93(2):181-192. Elliott S1, Sinclair A, Collins H, Rice L, 
Jelkmann W. Progress in detecting cell-surface protein receptors: the erythropoietin receptor example 
 
In addition, in recent years, EPO has shown 
protective effect against apoptosis and on the 
ischemic heart, which can improve left ventricular 
function [8]. 
 





Clinically, iron supplements can be roughly 
divided into oral and intravenous administration 
categories. In the reticuloendothelial system of 
patients with uremia and disorder of iron release 
and iron malabsorption in the gastrointestinal 
tract, oral administration typically fails to fully 
meet EPO treatment requirements as far as iron 
demand in the bone marrow [9]. The utilization 
rate of intravenous iron supplementation, 
conversely, is fairly high and with little 
gastrointestinal reaction, which can increase the 
iron utilization and improve iron reserves, 
overcoming the reticuloendothelial system iron 
release barrier. 
 
Iron ions are released from the complexes of 
intravenous iron assisted by activated 
macrophages in the reticuloendothelial system. 
One part of iron bind with apoferritin to form 
serum ferritsin store in the cell, other part of iron 
bind with transferrin transferred to transferrin 
receptor on the surface of the immature red cell, 
in these process increases iron utilization and the 
body's iron reserves [10].Clinical observation has 
confirmed that on the basis of EPO treatment, 
and then increased the treatment of iron sucrose, 
can significantly improve the clinical efficacy, and 
the adverse reaction of the treatment with 
sucrose iron after the occurrence of low and mild, 




L-carnitine, an amino acid already prevalent 
within the tissues of the body, can influence the 
erythrocyte membrane phospholipid and 
acylation process and deformation capacity, 
stabilize the red cell membrane, and increase 
hematocrits to enhance the body’s resistance to 
various stresses [12]. Cell-level L-carnitine 
deficiency produces toxic effects, increases 
normal red cell osmotic fragility, shortens life 
expectancy, and may cause EPO resistance [13]. 
Aoun [14] reported that long-term use of EPO in 
hemodialysis patients accompanied by 
intravenous L-carnitine supplementation, after 
nine months of treatment, results in significantly 
increased hemoglobin (Hb) levels, likely because  
L-carnitine reduces erythrocyte lipid composition 
to improve the stability of the red cell membrane, 
reducing brittleness and prolonging the life of red 
blood cells. In addition, L-carnitine can improve 
Na-K-ATPase activity, then increase the 
conversion of erythrocyte fatty acids and 
oxidative phosphorylation. The effects of L-
carnitine on bone marrow progenitor cells of red 
blood cells may also improve the curative effect 
of EPO, correct the resistance to EPO, and 
reduce the amount of EPO used by the body 
[15]. L-carnitine has also been shown to 
decrease C-reactive protein (CRP), interleukin 1 
(IL-1), and tumor necrosis factor (TNF) level, as 
well as microinflammation in patients who are in 





Iron dextran is an intravenous iron treatment. 
After treatment with erythropoietin, anemia 
patients show increased use of iron and 
imbalance of iron storage in the body. The 
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efficacy of intravenous iron supplementation is 
good, but it can cause acute adverse reaction 
and delayed reaction similar to allergic reaction, 
such as respiratory problems, hypotension, chest 
pain, vasogenic edema, and urticaria [17]. Iron 
dextran dispersion tablets combined with L-
carnitine injection and erythropoietin can 
significantly improve EPO efficacy, reducing EPO 
and leading to significant improvement in anemia 
with fewer side effects, in addition to reducing 




In patients with chronic renal failure, the retention 
of metabolic products, the decrease of 
antioxidant activity, and the increase of oxidant 
activity, resulting in reduced glutathione levels 
and elevated levels of oxidized glutathione. Red 
blood cell membrane molecules form disulfide 
bonds, so that the aggregation of 
macromolecules on the red blood cell 
membrane, resulting in red blood cell 
deformation [19]. 
 
Glutathione, a three peptide compound 
comprised of glutamic acid, cysteine, and 
glycine, is an important metabolic regulator in the 
cell. It can provide thiol and cysteine and 
maintain normal metabolism and physiological 
activities in the cell so as to keep the cell 
membrane intact [20]. It also can combine with 
pro electrons or reactive oxygen species to 
eliminate lipid peroxide, which protects the cell 
from damage [21]. Treating chronic renal failure 
with exogenous reductive glutathione can 
improve the reduction of red blood cells, reduce 
the concentration of oxidized glutathione, 
decrease the ratio of oxidized/reduced 
glutathione, stabilize the red blood cell 
membrane, and prolong the life of the red blood 
cell [22]. Research has shown that the effects of 
supplemental reductive glutathione on anemia 




Vitamin C, also known as ascorbic acid, is a 
water-soluble vitamin absorbed by the body in 
the upper part of the small intestine. Vitamin C 
plays an important role in the oxidative reduction 
of metabolic reactions. Vitamin C is involved in 
collagen synthesis, scurvy prevention, gum and 
mouth health, atrophy prevention, prevention of 
artery hardening, antioxidant synthesis, and 
anemia treatment [24]. Vitamin C reduces ferric 
iron, promotes intestinal iron absorption, and 
improves iron utilization in the liver. In some 
hemodialysis patients, lack of vitamin C reduces 
dialysis clearance [25]. 
Intravenous application of vitamin C, however, 
ameliorates iron overload in patients with anemia 
and increases their hemoglobin level [26]. 
Vitamin C must be reasonably utilized to prevent 
side effects, including high serum uric acid, 
urinary tract stones, and reduced fertility have 
been reported [27]. 
 
Enalapril and irbesartan 
 
Patients with chronic renal insufficiency have 
different degrees of renal anemia and 
hypertension. Enalapril, which hydrolysis into 
enalaprilat, can inhibit angiotensin converting 
enzyme reduces the content of angiotensin II 
causing the blood vessels to relax and blood 
pressure to drop, easing hypertension. Irbesartan 
is an angiotensin II receptor blocker that inhibits 
vascular angiotensin I from converting to 
angiotensin II, specifically antagonizing the 
vascular angiotensin converting enzyme (ACE) 1 
receptor [28]. By selectively block the binding of 
angiotensin II and angiotensin converting 
enzyme 1 receptors, it inhibits vasoconstriction 
and the release of aldosterone, then reduce 
blood pressure. Chronic renal disease 
hemodialysis patients given enalapril and 
irbesartan treatment show increased hemoglobin 
and red blood cell count, but the increase was 
smaller than the single use of EPO group [29]. In 
effect, hypertensive patients with chronic renal 
function disease must be given appropriate dose 
of erythropoietin to ensure enalapril 
effectiveness. 
 
Trace element copper 
 
The normal human body generally contains 70 – 
100 mg of copper [30], which is very important 
for human. Physiological changes of the body 
iron during hematopoiesis – including absorption, 
utilization, and storage of iron – are closely 
related to copper [31]. Copper make inorganic 
iron into organic iron, (in other words, can 
transform ferric iron) to push iron from storage 
into the bone marrow, accelerating the synthesis 
of hemoglobin and porphyrin. 
 
Copper can accelerate the maturation and the 
release of immature cells. Copper likely be 
supplemented to improve iron utilization during 
renal failure complicated with anemia in patients 
with low EPO response, but this has only been 
confirmed in animal experiments and yet needs 




Due to drug sensitivities and other individual 
differences, about 5 to 10 % of patients still do 
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not show sufficient hemoglobin level after the 
application of EPO (have EPO resistance) [33]. 
There are many reasons for EPO resistance: 
 
a). The state of micro-inflammatory in chronic 
dialysis patients have related with the 
decrease of renal clearance rate, 
inflammation and inflammatory cytokines.  
The inflammatory responses of IL-1, IL-6, 
TNF-α, and other cytokine secretions inhibit 
the proliferation of bone marrow 
hematopoietic stem cells, accelerating the 
destruction of red blood cells and hemoglobin, 
inhibiting the anti-apoptotic activity of EPO 
and interfering with iron metabolism, resulting 
in EPO resistance [34]. 
 
b). Secondary hyperthyroidism can lead to 
osteitis fibrosa, decreasing the bone marrow 
erythropoiesis and inhibiting endogenous 
EPO generation. 
 
(c).Aluminum poisoning - the binding of 
aluminum with iron transferrin interferes with  
the binding of iron with hemoglobin, which 
causes EPO resistance [35]. Aluminum can 
also inhibit hemoglobin synthase. 
 
d). EPO antibodies -- causes of EPO antibodies 
is unclear. Immune inhibitors can eliminate 
EPO antibodies in some patients [36]. 
 
(e) L-carnitine deficiency, during which the 
accumulation of metabolites affects carnitine 
intake. Partial clearance of L-carnitine in 
hemodialysis patients with varying degrees of 
L-carnitine deficiency can cause and 
aggravate anemia [37]. 
 
(f) Angiotensin converting enzyme inhibitor 
(ACEI) class of drugs are also related to EPO 
resistance, as first reported by Reuter et al 
[38]. A study involving dialysis patients. The 
activation of red blood cells after renal 
transplantation is related to the activation of 
the renin angiotensin system [39]. ACEI also 
improves the role of red blood cells in renal 
transplant recipients, and as such can reduce 
EPO resistance [40].Other researchers, 
however, have opposite view on the 
relationship between EPO resistance and 
ACEI [41]. 
 
(g) IL-1B genes -511 C/T and ACE I/D 
polymorphism are shown to be associated 
with EPO resistance in a study by Jeong et al 
[42] conducted on 167 hemodialysis patients. 
 
(h) Iron deficiency is also related to EPI 
resistance, for a few reasons. After EPO 
treatment, iron demand increases. 
Inflammation influences the release and 
utilization of iron. The barrier of iron 
absorption. Chronic blood loss, including the 
residual blood in pipe dialysis and dialysis, 
hemorrhagic cerebrovascular accident 
pathway, occult gastrointestinal hemorrhage 





EPO can significantly improve the level of 
oxygen in patients with renal anemia and related 
compromised immune function. Exogenous EPO 
and other drugs for renal anemia are safe and 
efficient. Recent years have seen increasingly 
extensive research on erythropoietin for the 
treatment of renal anemia. We believe that in the 
near future, the erythropoietin resistance problem 
will be solved and the benefits of the drug fully 
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